Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

AMOROLFINE FOR PEAK IDENTIFICATION CRS (10 MG)

AMOROLFINE FOR PEAK IDENTIFICATION CRS (10 MG)

ND

DISCOVER
EVEROLIMUS FOR IMPURITY C IDENTIFICATION CRS (10 MG)

EVEROLIMUS FOR IMPURITY C IDENTIFICATION CRS (10 MG)

ND

DISCOVER
ATAZANAVIR FOR SYSTEM SUITABILITY CRS (10 MG)

ATAZANAVIR FOR SYSTEM SUITABILITY CRS (10 MG)

ND

DISCOVER
LACOSAMIDE IMPURITY D CRS (10MG)

LACOSAMIDE IMPURITY D CRS (10MG)

NA

DISCOVER
PYRIMETHAMINE IMPURITY B CRS (20 MG)

PYRIMETHAMINE IMPURITY B CRS (20 MG)

ND

DISCOVER
ALFENTANIL HYDROCHLORIDE HYDRATE CRS - * NARC (30 MG)

ALFENTANIL HYDROCHLORIDE HYDRATE CRS - * NARC (30 MG)

ND

DISCOVER
TYPHAE POLLEN DRY EXTRACT FORSYSTEM SUITABILITY HRS (250 MG

TYPHAE POLLEN DRY EXTRACT FORSYSTEM SUITABILITY HRS (250 MG

ND

DISCOVER
SIMVASTATIN FOR SYSTEM SUITABILITY CRS (5 MG)

SIMVASTATIN FOR SYSTEM SUITABILITY CRS (5 MG)

ND

DISCOVER
ALFENTANIL IMPURITY D CRS (0.02 MG)

ALFENTANIL IMPURITY D CRS (0.02 MG)

ND

DISCOVER
DEXAMFETAMINE SULFATE CRS - *NARC (10 MG)

DEXAMFETAMINE SULFATE CRS - *NARC (10 MG)

ND

DISCOVER
BETACAROTENE FOR SYSTEM SUITABILITY CRS (10 MG)

BETACAROTENE FOR SYSTEM SUITABILITY CRS (10 MG)

ND

DISCOVER
AMFETAMINE SULFATE CRS - * NARC (10 MG)

AMFETAMINE SULFATE CRS - * NARC (10 MG)

ND

DISCOVER